Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endothelin blockade and insulin-stimulated vasodilation in T2D
NCT04907838Unknown
- Sponsor
- University of Southern Denmark
- Start
- May 2018
- Primary completion
- Jul 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of BQ-123 and BQ-788 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by University of Southern Denmark. Primary endpoints: Glucose infusion rate at 3.5 hours and Leg blood flow at 3.5 hours. Status: unknown.
02
Drugs
BQ-123BQ-788
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04907838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04907838.